Xilio Therapeutics (XLO) Stock Forecast, Price Target & Predictions
XLO Stock Forecast
Xilio Therapeutics stock forecast is as follows: an average price target of $7.00 (represents a 386.11% upside from XLO’s last price of $1.44) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
XLO Price Target
The average price target for Xilio Therapeutics (XLO) is $7.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $7.00 to $7.00. This represents a potential 386.11% upside from XLO's last price of $1.44.
XLO Analyst Ratings
According to 1 Wall Street analysts, Xilio Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for XLO stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Xilio Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Dec 21, 2022 | - | Chardan Capital | $7.00 | $1.97 | 255.33% | 386.11% |
The latest Xilio Therapeutics stock forecast, released on Dec 21, 2022 by Chardan Capital company, set a price target of $7.00, which represents a 255.33% increase from the stock price at the time of the forecast ($1.97), and a 386.11% increase from XLO last price ($1.44).
Xilio Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $1.44 | $1.44 | $1.44 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Xilio Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Xilio Therapeutics's last price of $1.44. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Dec 21, 2022 | Chardan Capital | - | Buy | Initialise |
Xilio Therapeutics's last stock rating was published by Chardan Capital on Dec 21, 2022. The company Initialise its XLO rating from "null" to "Buy".
Xilio Therapeutics Financial Forecast
Xilio Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - |
| Avg Forecast | $75.00M | $2.36M | $2.36M | $2.36M | $3.30M | $3.30M | $30.00M | $30.00M |
| High Forecast | $75.00M | $2.36M | $2.36M | $2.36M | $3.30M | $3.30M | $30.00M | $30.00M |
| Low Forecast | $75.00M | $2.36M | $2.36M | $2.36M | $3.30M | $3.30M | $30.00M | $30.00M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - |
Xilio Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. XLO's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Xilio Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - |
undefined analysts predict XLO's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Xilio Therapeutics's previous annual EBITDA (undefined) of $NaN.
Xilio Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - |
| Avg Forecast | $15.02M | $-5.20M | $-4.62M | $-4.62M | $-14.83M | $-14.25M | $-13.28M | $-6.35M |
| High Forecast | $15.02M | $-5.20M | $-4.62M | $-4.62M | $-14.83M | $-10.26M | $-13.28M | $-6.35M |
| Low Forecast | $15.02M | $-5.20M | $-4.62M | $-4.62M | $-14.83M | $-17.10M | $-13.28M | $-6.35M |
| Surprise % | - | - | - | - | - | - | - | - |
Xilio Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. XLO's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Xilio Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - |
Xilio Therapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to XLO last annual SG&A of $NaN (undefined).
Xilio Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - |
| Avg Forecast | $0.26 | $-0.09 | $-0.08 | $-0.08 | $-0.26 | $-0.25 | $-0.23 | $-0.11 |
| High Forecast | $0.26 | $-0.09 | $-0.08 | $-0.08 | $-0.26 | $-0.18 | $-0.23 | $-0.11 |
| Low Forecast | $0.26 | $-0.09 | $-0.08 | $-0.08 | $-0.26 | $-0.30 | $-0.23 | $-0.11 |
| Surprise % | - | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Xilio Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to XLO previous annual EPS of $NaN (undefined).
Xilio Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| RAPT | RAPT Therapeutics | $2.27 | $42.20 | 1759.03% | Hold |
| ANTX | AN2 Therapeutics | $1.08 | $8.75 | 710.19% | Buy |
| XLO | Xilio Therapeutics | $1.44 | $7.00 | 386.11% | Buy |
| MOLN | Molecular Partners | $6.06 | $29.00 | 378.55% | Buy |
| AVTE | Aerovate Therapeutics | $2.72 | $13.00 | 377.94% | Hold |
| ANEB | Anebulo Pharmaceuticals | $1.89 | $6.00 | 217.46% | Buy |
| ELYM | Eliem Therapeutics | $5.11 | $13.00 | 154.40% | Buy |
| MLYS | Mineralys Therapeutics | $13.50 | $30.00 | 122.22% | Buy |
| TYRA | Tyra Biosciences | $16.42 | $30.50 | 85.75% | Buy |
| DSGN | Design Therapeutics | $5.32 | $9.67 | 81.77% | Buy |
| ADAG | Adagene | $3.05 | $5.00 | 63.93% | Buy |
| EWTX | Edgewise Therapeutics | $34.48 | $45.00 | 30.51% | Buy |
| CNTB | Connect Biopharma | $1.20 | $1.50 | 25.00% | Buy |
| IKNA | Ikena Oncology | $1.72 | $1.33 | -22.67% | Buy |
| CYT | Cyteir Therapeutics | $3.02 | $2.00 | -33.77% | Sell |
XLO Forecast FAQ
Is Xilio Therapeutics a good buy?
Yes, according to 1 Wall Street analysts, Xilio Therapeutics (XLO) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of XLO's total ratings.
What is XLO's price target?
Xilio Therapeutics (XLO) average price target is $7 with a range of $7 to $7, implying a 386.11% from its last price of $1.44. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Xilio Therapeutics stock go up soon?
According to Wall Street analysts' prediction for XLO stock, the company can go up by 386.11% (from the last price of $1.44 to the average price target of $7), up by 386.11% based on the highest stock price target, and up by 386.11% based on the lowest stock price target.
Can Xilio Therapeutics stock reach $2?
XLO's average twelve months analyst stock price target of $7 supports the claim that Xilio Therapeutics can reach $2 in the near future.
What are Xilio Therapeutics's analysts' financial forecasts?
Xilio Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $66.6M (high $66.6M, low $66.6M), average EBITDA is $0 (high $0, low $0), average net income is $-48.711M (high $-44.722M, low $-51.561M), average SG&A $0 (high $0, low $0), and average EPS is $-0.843 (high $-0.774, low $-0.893). XLO's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $82.07M (high $82.07M, low $82.07M), average EBITDA is $0 (high $0, low $0), average net income is $577.6K (high $577.6K, low $577.6K), average SG&A $0 (high $0, low $0), and average EPS is $0.01 (high $0.01, low $0.01).